|
Skystar Bio-Pharmaceutical Company announced that it will commence product testing of two additional product dosage forms: oral solution and injectable soluble powder specifically formulated for Skystar veterinary line of medicines.
The product testing process will ensure that the new dosage forms will adhere to good manufacturing practices (GMP) consisting of: quality assurance of raw materials, record keeping of substances, production and process controls, warehouse and distribution protocols and safety standards. Skystar will then submit an application to the Chinese Ministry of Agriculture for GMP inspection and certification. Following GMP approval, and assuming market acceptance, management projects that the oral solution and injectable soluble powder line of veterinary medicines to have an estimated annual production capacity of twenty million units, potentially giving an additional five million dollars in annual revenue by fiscal 2011. Currently, the Skystar facility is manufacturing veterinary medicines that are delivered via injections, pulvis, powders, granules, tablets and premix forms.
Mr. Weibing Lu, chairman and CEO, commented, \"Skystar is looking to further expand the delivery methods for our line of veterinary medicines in response to market demand. We are also pleased to begin use of Skystar\'s completed veterinary medicine manufacturing facility at our Huxian plant in addition to the adjacent quality control and R&D building. Our goal for fiscal 2010 is to launch additional products in conjunction with the ramping of the Huxian plant\'s production capacity and will allow for the manufacture of eight of our most popular product categories covering over 150 different veterinary drug products.\" |
